Clinical Translation of Self‐Assembled Cancer Nanomedicines

Mi, Peng; Miyata, Kanjiro; Kataoka, Kazunori; Cabral, Horacio

doi:10.1002/adtp.202000159

Cited by 37 publications

(39 citation statements)

References 261 publications

(246 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 54 ] In addition, phase II clinical trials were successfully carried out using PGLA nanoparticles loaded with docetaxel (BIND‐014) and targeting a prostate specific membrane antigen in prostate cancer in 2016. [ 54 ]…”

Section: Polymeric Nanoparticle Systems For Bbb Transfermentioning

confidence: 99%

See 1 more Smart Citation

Development of Polymeric Nanoparticles for Blood–Brain Barrier Transfer—Strategies and Challenges

et al. 2021

View full text Add to dashboard Cite

Neurological disorders such as Alzheimer's disease, stroke, and brain cancers are difficult to treat with current drugs as their delivery efficacy to the brain is severely hampered by the presence of the blood-brain barrier (BBB). Drug delivery systems have been extensively explored in recent decades aiming to circumvent this barrier. In particular, polymeric nanoparticles have shown enormous potentials owing to their unique properties, such as high tunability, ease of synthesis, and control over drug release profile. However, careful analysis of their performance in effective drug transport across the BBB should be performed using clinically relevant testing models. In this review, polymeric nanoparticle systems for drug delivery to the central nervous system are discussed with an emphasis on the effects of particle size, shape, and surface modifications on BBB penetration. Moreover, the authors critically analyze the current in vitro and in vivo models used to evaluate BBB penetration efficacy, including the latest developments in the BBB-on-a-chip models. Finally, the challenges and future perspectives for the development of polymeric nanoparticles to combat neurological disorders are discussed.

show abstract

Section: Polymeric Nanoparticle Systems For Bbb Transfermentioning

confidence: 99%

Section: Polymeric Nanoparticle Systems For Bbb Transfermentioning

confidence: 99%

Development of Polymeric Nanoparticles for Blood–Brain Barrier Transfer—Strategies and Challenges

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In another pancreatic cancer mouse model, the Y-shaped block catiomer was utilized for delivering DNA-chimeric siRNAs, allowing for high transfection efficiency and protection from kidney filtration [ 338 ]. In 2020, this Y-shaped block catiomer has been directed to a phase I clinical trial for the treatment of triple negative breast cancer by delivering siRNA against positive regulatory domain-containing protein 14 [ 339 ].…”

Section: Translational Studies On Pll-based Nanomaterialsmentioning

confidence: 99%

Poly(α-l-lysine)-based nanomaterials for versatile biomedical applications: Current advances and perspectives

Zheng

Pan

Zhang

et al. 2021

Bioactive Materials

107

View full text Add to dashboard Cite

Poly(α- l -lysine) (PLL) is a class of water-soluble, cationic biopolymer composed of α- l -lysine structural units. The previous decade witnessed tremendous progress in the synthesis and biomedical applications of PLL and its composites. PLL-based polymers and copolymers, till date, have been extensively explored in the contexts such as antibacterial agents, gene/drug/protein delivery systems, bio-sensing, bio-imaging, and tissue engineering. This review aims to summarize the recent advances in PLL-based nanomaterials in these biomedical fields over the last decade. The review first describes the synthesis of PLL and its derivatives, followed by the main text of their recent biomedical applications and translational studies. Finally, the challenges and perspectives of PLL-based nanomaterials in biomedical fields are addressed.

show abstract

“…Progress in supramolecular chemistry and self‐assembled systems have addressed drug loading as well as offering versatility and more precise polymeric materials. [ 183 ] Initially amphiphilic co‐polymers were produced providing a hydrophobic core such as polyesters and poly(amino) esters. [ 184 ] Despite clinical success, the polyesters have limited functionality and more suited to more hydrophobic drugs and still require complex formulations to improve drug loading and tuneability of release.…”

Section: Developabilitymentioning

confidence: 99%

Highway to Success—Developing Advanced Polymer Therapeutics

England

Akhtar

2021

Advanced Therapeutics

View full text Add to dashboard Cite

Polymer therapeutics are advancing as an important class of drugs. Polymers have already demonstrated their value in extending the half‐life of proteins. They show great potential as delivery systems for improving the therapeutic index of drugs, via biophysical targeting and more recently with more precision targeting. They are also important for intracellular delivery of nucleic acid based drugs. The same frameworks that have been successfully applied to improve the small molecule drug development can be adopted. This approach together with improved pathophysiological disease knowledge and critical developability considerations, imperative given the size and complexity of polymer therapeutics, provides a structured framework that should improve their clinical translation and exploit their functionality and potential. Progress in understanding the right target, gaining the right tissue and cell exposure, ensuring the right safety, selecting the right patient population is discussed. The right commercial considerations are outlined and the need for a multi‐disciplinary approach is emphasized. Crucial developability factors together with scientific and technical advancements to enable pharmaceutical development of a quality robust product are addressed. It is argued that by applying this structured approach to their design and development, polymer therapeutics will continue to grow and develop as important next generation medicines.

show abstract

Clinical Translation of Self‐Assembled Cancer Nanomedicines

Cited by 37 publications

References 261 publications

Development of Polymeric Nanoparticles for Blood–Brain Barrier Transfer—Strategies and Challenges

Development of Polymeric Nanoparticles for Blood–Brain Barrier Transfer—Strategies and Challenges

Poly(α-l-lysine)-based nanomaterials for versatile biomedical applications: Current advances and perspectives

Highway to Success—Developing Advanced Polymer Therapeutics

Contact Info

Product

Resources

About